The global hospital injectable drugs market is anticipated to grow at a significant CAGR during the forecast period. The major factors that are expected to boost the market growth include the rising demand for biologics, rising prevalence of chronic diseases, and the benefits of injectables (convenience, ease of use, and reduced pain). These factors have increased the demand for devices such as safety syringes, prefilled syringes, and autoinjectors, which in turn, is expected to boost the growth of the market. Moreover, as biologics are mainly administered through the injectable route, the significant growth in the biologics market is expected to accelerate the market growth in the coming years.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/hospital-injectable-drugs-market
Over the years, the use of injectable contraceptives has increased significantly. This increased use of injectable contraceptives can mainly be attributed owing to their high efficacy. Injectable contraceptives are not required to be taken daily; they can be administered once every month or once every three months and are considered to be one of the safer modes of pregnancy prevention. They prevent pregnancy 99% of the time, when administered correctly. Owing to these reasons, the demand for contraceptive injectables is expected to drive the market in the future. Furthermore, new launches have been witnessed in the market. For instance, in December 2021, the US FDA approved GSK’s Apretude, or cabotegravir, to reduce the risk of sexually acquired HIV. The endorsement provides users the first long-acting injected option in the pre-exposure prophylaxis (PrEP) setting. With this approval, Apretude will go up against Gilead’s well-established Truvada and its generic, plus the California biotech’s newer Descovy.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Type
o By Application
- Regions covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
Competitive Landscape: Gilead Sciences, Inc., GlaxoSmithKline plc, and Baxter International Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Hospital Injectable Drugs Market Report by Segment
By Application
- Cardiology and Metabolic Disorders,
- Oncology
- Neurology
- Gastroenterology
- Pain
- Infectious Diseases
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- E-Commerce
A full report of Hospital Injectable Drugs Market is available at: https://www.omrglobal.com/industry-reports/hospital-injectable-drugs-market
Hospital Injectable Drugs Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Baxter International Inc.
